[R01] Selective loss of HLA gene products in driving unique breast cancer immunobiology
Ente: National Cancer Institute
Scadenza: 2031-05-31
Importo max: $695,884
Paese: US
Descrizione
Despite the success of immune checkpoint inhibition (ICI) in cancer therapy, intrinsic and acquired resistance to
therapy are common in triple-negative breast cancer (TNBC) patients and the mechanisms are poorly
understood. CD8+ cytotoxic T cell recognition of MHC-I-peptide complexes (pMHC-I) is cri
Settori: National Cancer Institute
Registrati gratis su Bandolo per trovare bandi compatibili con la tua azienda.